What Are Wall Street Analysts’ Target Price for Medtronic Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2025
0mins
Source: NASDAQ.COM
Company Overview and Performance: Medtronic plc, based in Galway, Ireland, has a market cap of $105.6 billion and operates through various medical device segments. Despite a marginal rise in shares over the past year, it has underperformed compared to the S&P 500 Index and the iShares U.S. Medical Devices ETF.
Recent Developments and Analyst Ratings: The company reported mixed Q3 2025 results with revenue growth and an adjusted EPS that surpassed estimates. Analysts maintain a "Moderate Buy" consensus rating, with expectations for a nearly 5% increase in adjusted EPS for fiscal 2025, while price targets suggest potential upside for the stock.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 78.300
Low
102.00
Averages
111.76
High
120.00
Current: 78.300
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three High-Yield Stocks for Monthly Dividends
- AbbVie's Strong Financials: AbbVie, with a market cap of approximately $370 billion, generated over $61 billion in revenue last year and $20 billion in operating income, demonstrating its ability to grow despite patent expirations, while its 3.3% dividend yield significantly exceeds the S&P 500 average of 1.1%.
- Medtronic's Stability: Medtronic, valued at $101 billion, reported a 9% revenue increase in its latest quarter, with free cash flow of $5.4 billion easily covering its $3.6 billion annual dividend payout, resulting in a 3.6% yield, making it an ideal choice for income-focused investors.
- Enbridge's Consistent Growth: Enbridge, with a market cap of $119 billion, has raised its dividend for 31 consecutive years, with a recent 3% increase, yielding 5.2%, the highest among the listed stocks, and despite a payout ratio over 100%, its distributable cash flow indicates strong financial health.
- Diversified Investment Strategy: By investing in AbbVie, Medtronic, and Enbridge, investors can achieve monthly cash flow, leveraging the different dividend payment schedules of these companies to enhance the stability of their investment portfolio.
See More
Analysis of High-Yield Stock Investment Strategies
- AbbVie's Financial Strength: AbbVie, with a market cap of approximately $370 billion, generated over $61 billion in revenue and $20 billion in operating income last year despite patent expirations, ensuring a safe 3.3% dividend yield backed by robust financials.
- Medtronic's Stable Growth: Medtronic's revenue rose by 9% in the latest quarter, exceeding guidance, with free cash flow of $5.4 billion over the past 12 months, significantly surpassing its $3.6 billion annual dividend payout, offering a 3.6% yield ideal for income-focused investors.
- Enbridge's Consistent Dividends: Enbridge has increased its dividend for 31 consecutive years, with a recent 3% hike bringing its yield to 5.2%; despite a payout ratio over 100%, its distributable cash flow assessment indicates strong financial health, making it a solid long-term investment.
- Diversified Dividend Portfolio: By investing in stocks like AbbVie, Medtronic, and Enbridge, which pay dividends at different times, investors can achieve stable monthly cash flow, enhancing portfolio income, particularly beneficial for retirees or those seeking to boost their earnings.
See More
Healthcare Giants Face Challenges and Opportunities
- Intuitive Surgical Competition: Intuitive Surgical is facing intensified competition from Medtronic and other healthcare giants in the robotic-assisted surgery market, which could impact its market share and profitability, although the company continues to post strong financial results with revenue and earnings growth in Q1.
- Valuation Risks: Intuitive Surgical's current P/E ratio stands at 44.3, significantly higher than the healthcare sector's average of 16.5, which may deter short-term investors despite the stock's long-term appeal for those willing to hold.
- Vertex Pharmaceuticals Growth Slowdown: Vertex Pharmaceuticals' shares have declined 14% over the past year; while its cystic fibrosis drugs continue to generate stable revenue, the company's diversification efforts have not yielded significant results, leading to underperformance in its stock price.
- Future Potential Remains Strong: Despite challenges, Vertex Pharmaceuticals' cystic fibrosis business is expected to remain viable until the mid-2030s, and its development of new therapies targeting patients not eligible for current treatments could drive future sales growth.
See More
Healthcare Giants Face Challenges and Opportunities Ahead
- Underperformance: Both Intuitive Surgical and Vertex Pharmaceuticals have significantly underperformed the market this year, facing challenges such as tariffs on medical devices and setbacks in drug diversification, which have shaken investor confidence in their growth prospects.
- Increased Competition: Intuitive Surgical is facing heightened competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; while its financial performance remains strong, the pressure on market share could impact its long-term profitability.
- Valuation Concerns: Intuitive Surgical's current P/E ratio stands at 44.3, significantly higher than the healthcare industry's average of 16.5, and although its long-term investment value is still viewed positively, the high valuation may cause short-term investors to feel uneasy.
- Future Growth Potential: Vertex Pharmaceuticals' cystic fibrosis drug business is expected to continue generating revenue until the mid-2030s, and its plans for new drug development and market expansion could drive future revenue growth, despite a current stock price decline of 14%.
See More
Dexcom Reiterates Full-Year Revenue Forecast After Beating Estimates
- Quarterly Performance Beat: Dexcom reported quarterly revenue of $1.19 billion, a 15% year-over-year increase, surpassing analysts' expectations of $1.18 billion, indicating strong demand for its continuous glucose monitors.
- Profitability Improvement: The company posted an adjusted earnings per share of 56 cents, exceeding estimates of 47 cents, reflecting effective strategies in cost control and market demand management.
- Product Innovation and Market Expansion: Dexcom expanded the launch of the Dexcom G7 15-day sensor in the U.S. and added new meal-logging features to the Stelo platform, further solidifying its market position in diabetes care.
- Intensifying Market Competition: With rising awareness of diabetes care and broader insurance coverage, Dexcom faces fierce competition from Medtronic and Abbott, prompting continuous innovation to maintain market share.
See More
Orchestra BioMed Secures FDA Breakthrough Device Designation for AVIM Therapy
- FDA Breakthrough Designation: Orchestra BioMed has received a second Breakthrough Device Designation from the FDA for AVIM Therapy, covering over 7.7 million adults with uncontrolled hypertension despite medication, marking a significant advancement in cardiovascular treatment.
- Clinical Trial Support: This designation aligns with the ongoing BACKBEAT global pivotal trial aimed at evaluating the safety and efficacy of AVIM Therapy in hypertensive patients, further strengthening the strategic partnership with Medtronic.
- Reimbursement Pathway Optimization: The Breakthrough Device Designation supports favorable reimbursement pathways, including New Technology Add-on Payment (NTAP) and Transitional Pass-Through (TPT) payments, which will facilitate timely patient access and provider adoption.
- Significant Market Potential: As a bioelectronic treatment designed to substantially lower blood pressure in hypertensive patients, AVIM Therapy is expected to generate multi-billion-dollar market opportunities for Orchestra BioMed, further solidifying its leadership position in the medical device market.
See More
Three High-Yield Stocks for Monthly Dividends
- AbbVie's Strong Financials: AbbVie, with a market cap of approximately $370 billion, generated over $61 billion in revenue last year and $20 billion in operating income, demonstrating its ability to grow despite patent expirations, while its 3.3% dividend yield significantly exceeds the S&P 500 average of 1.1%.
- Medtronic's Stability: Medtronic, valued at $101 billion, reported a 9% revenue increase in its latest quarter, with free cash flow of $5.4 billion easily covering its $3.6 billion annual dividend payout, resulting in a 3.6% yield, making it an ideal choice for income-focused investors.
- Enbridge's Consistent Growth: Enbridge, with a market cap of $119 billion, has raised its dividend for 31 consecutive years, with a recent 3% increase, yielding 5.2%, the highest among the listed stocks, and despite a payout ratio over 100%, its distributable cash flow indicates strong financial health.
- Diversified Investment Strategy: By investing in AbbVie, Medtronic, and Enbridge, investors can achieve monthly cash flow, leveraging the different dividend payment schedules of these companies to enhance the stability of their investment portfolio.
See More
Analysis of High-Yield Stock Investment Strategies
- AbbVie's Financial Strength: AbbVie, with a market cap of approximately $370 billion, generated over $61 billion in revenue and $20 billion in operating income last year despite patent expirations, ensuring a safe 3.3% dividend yield backed by robust financials.
- Medtronic's Stable Growth: Medtronic's revenue rose by 9% in the latest quarter, exceeding guidance, with free cash flow of $5.4 billion over the past 12 months, significantly surpassing its $3.6 billion annual dividend payout, offering a 3.6% yield ideal for income-focused investors.
- Enbridge's Consistent Dividends: Enbridge has increased its dividend for 31 consecutive years, with a recent 3% hike bringing its yield to 5.2%; despite a payout ratio over 100%, its distributable cash flow assessment indicates strong financial health, making it a solid long-term investment.
- Diversified Dividend Portfolio: By investing in stocks like AbbVie, Medtronic, and Enbridge, which pay dividends at different times, investors can achieve stable monthly cash flow, enhancing portfolio income, particularly beneficial for retirees or those seeking to boost their earnings.
See More
Healthcare Giants Face Challenges and Opportunities
- Intuitive Surgical Competition: Intuitive Surgical is facing intensified competition from Medtronic and other healthcare giants in the robotic-assisted surgery market, which could impact its market share and profitability, although the company continues to post strong financial results with revenue and earnings growth in Q1.
- Valuation Risks: Intuitive Surgical's current P/E ratio stands at 44.3, significantly higher than the healthcare sector's average of 16.5, which may deter short-term investors despite the stock's long-term appeal for those willing to hold.
- Vertex Pharmaceuticals Growth Slowdown: Vertex Pharmaceuticals' shares have declined 14% over the past year; while its cystic fibrosis drugs continue to generate stable revenue, the company's diversification efforts have not yielded significant results, leading to underperformance in its stock price.
- Future Potential Remains Strong: Despite challenges, Vertex Pharmaceuticals' cystic fibrosis business is expected to remain viable until the mid-2030s, and its development of new therapies targeting patients not eligible for current treatments could drive future sales growth.
See More
Healthcare Giants Face Challenges and Opportunities Ahead
- Underperformance: Both Intuitive Surgical and Vertex Pharmaceuticals have significantly underperformed the market this year, facing challenges such as tariffs on medical devices and setbacks in drug diversification, which have shaken investor confidence in their growth prospects.
- Increased Competition: Intuitive Surgical is facing heightened competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; while its financial performance remains strong, the pressure on market share could impact its long-term profitability.
- Valuation Concerns: Intuitive Surgical's current P/E ratio stands at 44.3, significantly higher than the healthcare industry's average of 16.5, and although its long-term investment value is still viewed positively, the high valuation may cause short-term investors to feel uneasy.
- Future Growth Potential: Vertex Pharmaceuticals' cystic fibrosis drug business is expected to continue generating revenue until the mid-2030s, and its plans for new drug development and market expansion could drive future revenue growth, despite a current stock price decline of 14%.
See More
Dexcom Reiterates Full-Year Revenue Forecast After Beating Estimates
- Quarterly Performance Beat: Dexcom reported quarterly revenue of $1.19 billion, a 15% year-over-year increase, surpassing analysts' expectations of $1.18 billion, indicating strong demand for its continuous glucose monitors.
- Profitability Improvement: The company posted an adjusted earnings per share of 56 cents, exceeding estimates of 47 cents, reflecting effective strategies in cost control and market demand management.
- Product Innovation and Market Expansion: Dexcom expanded the launch of the Dexcom G7 15-day sensor in the U.S. and added new meal-logging features to the Stelo platform, further solidifying its market position in diabetes care.
- Intensifying Market Competition: With rising awareness of diabetes care and broader insurance coverage, Dexcom faces fierce competition from Medtronic and Abbott, prompting continuous innovation to maintain market share.
See More
Orchestra BioMed Secures FDA Breakthrough Device Designation for AVIM Therapy
- FDA Breakthrough Designation: Orchestra BioMed has received a second Breakthrough Device Designation from the FDA for AVIM Therapy, covering over 7.7 million adults with uncontrolled hypertension despite medication, marking a significant advancement in cardiovascular treatment.
- Clinical Trial Support: This designation aligns with the ongoing BACKBEAT global pivotal trial aimed at evaluating the safety and efficacy of AVIM Therapy in hypertensive patients, further strengthening the strategic partnership with Medtronic.
- Reimbursement Pathway Optimization: The Breakthrough Device Designation supports favorable reimbursement pathways, including New Technology Add-on Payment (NTAP) and Transitional Pass-Through (TPT) payments, which will facilitate timely patient access and provider adoption.
- Significant Market Potential: As a bioelectronic treatment designed to substantially lower blood pressure in hypertensive patients, AVIM Therapy is expected to generate multi-billion-dollar market opportunities for Orchestra BioMed, further solidifying its leadership position in the medical device market.
See More
